| Autor: |
Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica D., Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert Peter, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Diaz, Miguel Angel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo F., Hossain, Nasheed M., Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell S., Ciurea, Stefan, Schouten, Harry C., Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean A., Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil D., Pawarode, Attaphol, Bacher, Vera Ulrike, Grunwald, Michael R., Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard C., Seo, Sachiko, Olsson, Richard F., George, Biju, de Lima, Marcos, Hourigan, Christopher S., Sandmaier, Brenda M., Litzow, Mark, Kebriaei, Partow, Saber, Wael, Weisdorf, Daniel |
| Zdroj: |
Biology of Blood and Marrow Transplantation (Science Direct); 20240101, Issue: Preprints |
| Abstrakt: |
•Myeloablative conditioning (MAC) results in lower relapse and better disease-free survival (DFS) after hematopoietic cell transplantation for acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) with low/intermediate-risk Disease Risk Index (DRI).•MAC and RIC regimens yield similar DFS and overall survival for AML/MDS with high/very high-risk DRI. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
